Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230957 | PMC |
| http://dx.doi.org/10.3390/jcm9041241 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Facial tinea incognito: a clinical, dermoscopic and mycological study of 38 cases.
Eur J Dermatol
April 2023
Department of Dermatology, Jeonbuk National University Medical School, Jeonju, Korea, Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Background: Tinea incognito (TI) is a dermatophytic infection of the skin that is modified by steroid use. As a result, it shows atypical clinical presentations that can lead to misdiagnosis. TI occurring on the face is most frequently misdiagnosed as cutaneous fungal infection, however, very limited information is available on facial TI.
View Article and Find Full Text PDFDupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis.
J Dermatol
January 2023
Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a typical type-2 inflammation involving T-helper type-2 cells and impairing quality of life due to nasal obstruction, discharge and reduced sense of smell. Recently, the anti-IL4Rα antibody dupilumab was approved for CRSwNP. While dermatologic side effects in patients treated with dupilumab for atopic dermatitis are frequently observed, there is limited knowledge about these effects in patients with CRSwNP.
View Article and Find Full Text PDFDemodicosis Imitating Acne Vulgaris: A Case Report.
Clin Cosmet Investig Dermatol
March 2022
School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok, 10110, Thailand.
Demodicosis is caused by mite infestation and can present with a variety of clinical manifestations, including pityriasis folliculorum type, rosacea-like type, folliculitis-like type and perioral dermatitis-like type. Therefore, this skin condition is often misdiagnosed or underdiagnosed. This report presents a 19-year-old woman with a history of pityriasis folliculorum type demodicosis and successful treatment with oral ivermectin.
View Article and Find Full Text PDFInfiltrative Erythemas and Nodules on a Unilateral Cheek Following Inappropriate Use of a Topical Steroid.
Yonago Acta Med
February 2022
Division of Dermatology, Department of Medicine of Sensory and Motor Organs, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
Article Synopsis
- A 50-year-old Japanese woman presented with red nodules on her left cheek after using topical corticosteroids for 4 years, leading to a diagnosis of unilateral steroid-induced rosacea-like dermatitis (SIRD).
- A skin biopsy revealed inflammation and damage to hair follicles, confirming the diagnosis linked to long-term steroid use.
- After stopping the steroids and treating with benzoyl peroxide, the woman's nodules improved significantly over 18 months, emphasizing the need for careful steroid use and proper diagnosis for facial skin issues.
Demodex Folliculitis and Recent Dupilumab Administration.
Pediatrics
May 2021
Cooper Medical School of Rowan University, Camden, New Jersey.
Two adolescent boys presented with acute acneiform eruptions in the setting of recent dupilumab administration. Subsequent investigation via direct scraping of pustules revealed live Demodex mite colonization of the face. These adolescent patients represent a population not commonly associated with Demodex folliculitis, and we theorize their baseline commensal Demodex mite population may have increased as a consequence of dupilumab-induced, focused immunomodulation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!